Opus Genetics, Inc.

Stocks

IRD

US67577R1023

Market Closed - Nasdaq 06:00:00 03/10/26 am AEST			5-day change	1st Jan Change
4.580 ^USD	+1.55%		-3.78%	+127.86%

21/09	Opus Genetics, Inc.(NasdaqCM:IRD) added to S&P Global BMI Index	CI
11/09	HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers	RE

Transcript : Opus Genetics, Inc. - Special Call

Published on 06/17/2026 at 06:50 am AEST - Modified on 06/26/2026 at 04:51 am AEST

S&P Capital IQ

Presenter Speech
Benjamin Yerxa (Executives)

Good morning, and thank you for joining us today to delve into our gene therapy pipeline with a focus on our earlier-stage programs. As a reminder, this

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Opus Genetics, Inc.

21/09	Opus Genetics, Inc.(NasdaqCM:IRD) added to S&P Global BMI Index	CI
11/09	HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers	RE
10/09	Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating	MT
10/09	Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating	MT
10/09	Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of Opgx-Best1 and Successful Fda Type C Meeting with Potential Phase 3 Dosing in 2027	CI
10/09	Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial	MT
10/09	Opus Genetics Shares Reach 52-Week High on Clinical Trial, FDA Progress	DJ
10/09	Opus Genetics, Inc. - Special Call
10/09	Top Midday Gainers	MT
10/09	Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating	MT
09/09	Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial	MT
07/08	RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating	MT
07/08	Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder	MT
03/08	Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease	CI